Xiao Qiuping, Hong Yanqiu, Geng Xuesi
Anorectal Branch, Xiamen Hospital of Traditional Chinese Medicine Affiliated to Fujian University of Traditional Chinese Medicine, Xiamen, Fujian Province, China.
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
Gastroenterol Res Pract. 2025 May 27;2025:5790162. doi: 10.1155/grp/5790162. eCollection 2025.
Changrun Formula (CRF) is a representative traditional Chinese medicine prescription for functional constipation (FC). However, the mechanism by which CRF alleviates FC remains unclear. Therefore, this study aimed to investigate the therapeutic mechanism of CRF in an FC rat model. A total of 72 healthy SD rats were selected and randomly divided into six groups: the blank group, model group, hemp seed pill (HSP) group, high-dose CRF group, medium-dose CRF group, and low-dose CRF group. Except for the blank group, all the other groups were administered compound diphenoxylate via oral gavage to establish the FC rat model with impaired intestinal motility. The expression of genes related to intestinal motility in the colon tissues of rats was analyzed using Western blotting and real-time PCR. The effect of CRF on isolated colonic smooth muscle was assessed through electrophysiological analysis. Compared with the blank group, the other groups exhibited a longer time to expel the first black stool and a reduced number of fecal particles within 6 h, confirming the successful establishment of the FC rat model. Furthermore, the expressions of HCN1, c-kit, and SP in the colon tissue of the model group were significantly decreased, while the expression level of VIP was significantly increased. HCN1 was found to colocalize with c-kit, SP, and VIP. Treatment of CRF (high and medium doses) significantly increased the expressions of c-kit, SCF, HCN1, and HCN2, enhanced the contractile movement of colonic smooth muscle, and improved muscle tension. CRF likely improves intestinal motility by targeting HCN1 and HCN2 ion channels and the SCF/c-kit signaling pathway, thereby alleviating FC symptoms in rats.
畅润方（CRF）是治疗功能性便秘（FC）的代表性中药方剂。然而，CRF缓解FC的机制尚不清楚。因此，本研究旨在探讨CRF在FC大鼠模型中的治疗机制。选取72只健康SD大鼠，随机分为6组：空白组、模型组、麻子仁丸（HSP）组、CRF高剂量组、CRF中剂量组和CRF低剂量组。除空白组外，其余各组均通过灌胃给予复方地芬诺酯，以建立肠道运动功能受损的FC大鼠模型。采用蛋白质免疫印迹法和实时荧光定量PCR法分析大鼠结肠组织中肠道运动相关基因的表达。通过电生理分析评估CRF对离体结肠平滑肌的作用。与空白组相比，其他各组首次排出黑便的时间延长，6小时内粪便颗粒数量减少，证实FC大鼠模型建立成功。此外，模型组结肠组织中HCN1、c-kit和SP的表达显著降低，而VIP的表达水平显著升高。发现HCN1与c-kit、SP和VIP共定位。CRF（高剂量和中剂量）治疗可显著增加c-kit、SCF、HCN1和HCN2的表达，增强结肠平滑肌的收缩运动，提高肌张力。CRF可能通过靶向HCN1和HCN2离子通道以及SCF/c-kit信号通路改善肠道运动，从而缓解大鼠的FC症状。
